What is Champions Oncology, Inc.'s (CSBR) StockRank?

MoatMap's StockRank for Champions Oncology, Inc. (CSBR) is 54/100, with a Hold signal. This is a composite score combining Quality (63), Value (36), and Momentum (49) factor ranks across MoatMap's 20,000+ stock universe.

Does Champions Oncology, Inc. have an economic moat?

Champions Oncology, Inc. (CSBR) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Champions Oncology, Inc. a buy, hold, or sell?

MoatMap's current signal for Champions Oncology, Inc. (CSBR) is Hold, based on a StockRank of 54/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Champions Oncology, Inc. in?

Champions Oncology, Inc. (CSBR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CSBR

HOLD

Champions Oncology, Inc. · Healthcare · United States · $92M · Avg Vol: $45K/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-47.6%

D/E

1.1x

Dividend %

—

COMPANY DESCRIPTION

Champions Oncology, Inc. develops and sells advanced technology solutions and services to personalize the development and clinical use of oncology drugs. The company's proprietary TumorGraft platform utilizes patient-derived xenograft (PDX) models to predict patient responses to cancer therapies, establishing a strong moat in translational oncology. It is a leading niche provider of preclinical and clinical testing services for global pharmaceutical developers.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	49.1M	53.9M	50.2M	56.9M	5.1%	57.9M
EPS	0.04	-0.39	-0.54	0.34	104.1%	-0.18
Shares	13.5M	13.5M	13.6M	13.7M	+1.4%	13.9M
Debt	9.5M	8.6M	7.4M	6.1M	-13.6%	5.0M
Equity	9.1M	4.6M	-1.9M	3.8M	-25.4%	—
Op CF	6.5M	4.0M	-6.1M	7.4M	4.4%	4.4M
Inv CF	-2.4M	-2.9M	-0.8M	-0.4M	—	—
Fin CF	0.2M	11.0K	-0.5M	0.2M	—	—

Loading 1Y...

PRICE (1Y)-1.0%

SMA 50SMA 200

$5.81

RSI (14)

31.5

52W High

$9.63

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

57.1%99.4

ROE

-47.6%18.5

GP/Assets

82.2%96.1

Op. Margin

-1.1%34.1

FCF/Assets

14.5%92.9

Piotroski

893.4

Int. Cover

—N/A

D/E Ratio

1.14x13.1

Current Ratio

0.98x10.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-101.9x25.0

P/FCF

19.6x65.6

P/B

18.9x6.2

P/S

1.4x76.8

Div Yield

—N/A

Momentum

52W High %

60%35.5

RS 6M

-21%44.0

SMA 50/200

0.95x53.7

EPS Rev 4W

0.0%64.0

EPS Rev 12W

—N/A

EPS Improve

+156%83.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$92M

P/E (Forward)

58.1x

Gross Margin

45.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CSBR are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CSBR	Champions Oncology, Inc.(you)	$92M	54	HOLD
FBIO	Fortress Biotech, Inc.	$92M	49	HOLD
ORMP	Oramed Pharmaceuticals Inc.	$191M	57	HOLD
LONA	LeonaBio, Inc.	$88M	33	SELL
BOLD	Boundless Bio, Inc.	$58M	41	HOLD
CUE	Cue Biopharma, Inc.	$107M	33	SELL
DTIL	Precision BioSciences, Inc.	$188M	44	HOLD
AGEN	Agenus Inc.	$126M	33	SELL
IMUX	Immunic, Inc.	$208M	38	HOLD
SPRO	Spero Therapeutics, Inc.	$131M	80	STRONG BUY

Peer medians: ROE -21.2% · P/E 27.1x · Gross margin 44.3%

Champions Oncology, Inc. (CSBR) — Stock Score Summary

Champions Oncology, Inc. (CSBR) has a MoatMap StockRank of 54/100 based on Quality (63/100), Value (36/100), and Momentum (49/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$5.81
Market Cap	$92M
P/E (Forward)	58.10
Price/Book	18.86
Return on Equity	-47.6%
Return on Invested Capital	57.1%
Debt/Equity	114.19
Gross Margin	45.9%
Operating Margin	-1.1%
Revenue Growth	-2.8%
Free Cash Flow	$5M

Champions Oncology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Champions Oncology, Inc.’s (CSBR) StockRank?: MoatMap’s StockRank for Champions Oncology, Inc. (CSBR) is 54/100, with a Hold signal. It is a composite of Quality (63), Value (36), and Momentum (49) factor ranks across MoatMap’s 20,000+ stock universe.
Does Champions Oncology, Inc. have an economic moat?: Champions Oncology, Inc. (CSBR) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Champions Oncology, Inc. a buy, hold, or sell?: MoatMap’s current signal for Champions Oncology, Inc. (CSBR) is Hold, based on a StockRank of 54/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Champions Oncology, Inc. in?: Champions Oncology, Inc. (CSBR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).